|
gptkbp:instance_of
|
gptkb:pharmaceuticals
|
|
gptkbp:administered_by
|
gptkb:tablet
|
|
gptkbp:atccode
|
L01 XX
|
|
gptkbp:bioavailability
|
high
|
|
gptkbp:casnumber
|
1234567-89-0
|
|
gptkbp:chemical_formula
|
C22 H24 N4 O3 S
|
|
gptkbp:clinical_trial
|
gptkb:Europe
gptkb:Asia
gptkb:USA
gptkb:Sunesis_Pharmaceuticals
Phase 1
pending
Phase 2
Phase 3
|
|
gptkbp:collaborations
|
academic institutions
pharmaceutical companies
|
|
gptkbp:developed_by
|
gptkb:Sunesis_Pharmaceuticals
|
|
gptkbp:discovery_year
|
gptkb:2010
|
|
gptkbp:dosage_form
|
once daily
|
|
gptkbp:drug_interactions
|
CYP3 A4 inducers
CYP3 A4 inhibitors
|
|
gptkbp:duration
|
varies
|
|
gptkbp:efficacy_study
|
ongoing
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:formulation
|
oral tablet
|
|
gptkbp:funding
|
gptkb:investors
grants
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Cerdulatinib
|
|
gptkbp:indication
|
gptkb:Oncology
|
|
gptkbp:invention
|
patented
|
|
gptkbp:is_effective_against
|
promising
|
|
gptkbp:is_tested_for
|
clinical trials
|
|
gptkbp:lifespan
|
approximately 12 hours
|
|
gptkbp:market_position
|
not approved
|
|
gptkbp:mechanism_of_action
|
inhibitor of SYK and JAK
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:patient_population
|
relapsed/refractory patients
|
|
gptkbp:research_areas
|
oncology
hematology
|
|
gptkbp:route_of_administration
|
oral
|
|
gptkbp:safety_features
|
acceptable
|
|
gptkbp:safety_measures
|
ongoing
|
|
gptkbp:service_frequency
|
daily
|
|
gptkbp:side_effect
|
gptkb:anemia
fatigue
headache
nausea
diarrhea
thrombocytopenia
neutropenia
|
|
gptkbp:status
|
investigational
|
|
gptkbp:structure
|
gptkb:Atom
|
|
gptkbp:target_audience
|
gptkb:children
adults
|
|
gptkbp:targets
|
gptkb:SYK
JAK
|
|
gptkbp:treatment
|
with other agents
|
|
gptkbp:used_for
|
treatment of cancer
|
|
gptkbp:bfsParent
|
gptkb:Portola_Pharmaceuticals
|
|
gptkbp:bfsLayer
|
6
|